914299-14-2

Upstream product

• 914299-13-1 2-(4-bromo-2-methylphenyl)pyrrolidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 99548-55-7 4-bromo-2-methyl-benzoic acid methyl ester 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 914299-11-9 C₁₄H₁₄BrNO₂ 
• 914299-12-0 C₁₁H₁₂BrN 

Downstream Products

• 914299-15-3 N-Boc-3-methyl-4-pyrrolidin-2-ylbenzoic acid methyl ester 
• 914299-93-7 3-methyl-4-pyrrolidin-2-ylbenzoic acid methyl ester 
• 914299-16-4 methyl 4-{1-[5-chloro-2,4-bis(methoxymethoxy)benzoyl]pyrrolidin-2-yl}-3-methylbenzoate 
• 914299-17-5 4-{1-[5-chloro-2,4-bis(methoxymethoxy)benzoyl]pyrrolidin-2-yl}-3-methylbenzoic acid 
• 914299-18-6 4-{1-[5-chloro-2,4-bis(methoxymethoxy)benzoyl]pyrrolidin-2-yl}-N-ethyl-3-methylbenzamide 

Relevant academic research and scientific papers

HETEROCYCLIC SUBSTITUTED UREAS, FOR USE AGAINST CANCER

The application relates to heterocyclic urea derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation.

Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone

Information from X-ray crystal structures were used to optimize the potency of a HTS hit in a Hsp90 competitive binding assay. A class of novel and potent small molecule Hsp90 inhibitors were thereby identified. Enantio-pure compounds 31 and 33 were potent in PGA-based competitive binding assay and inhibited proliferation of various human cancer cell lines in vitro, with IC50 values averaging 20 nM.

AMIDE RESORCINOL COMPOUNDS

The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as HSP-90 inhibitors.